RFRivers Fragneau

Rivers Fragneau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rivers Fragneau has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Allison L. Bartlett

    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    1 shared publication
  • Andrica C. H. de Vries

    11Sophia Children’s Hospital, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands

    1 shared publication
  • Arivarasan D. Karunamurthy

    18Department of Dermatology, University of Pittsburgh School of Medicine, UPMC, Pittsburgh, PA

    1 shared publication
  • Arndt Borkhardt

    Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany

    1 shared publication
  • Arunaloke Bhattacharya

    26Department of Pediatrics, Institute of Child Health, Kolkata, India

    1 shared publication
  • Ashish R. Kumar

    Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

    1 shared publication

Latest Publications

  • Open Access

    NTRK1-rearranged histiocytosis: clinicopathologic and molecular features

    by Rivers Fragneau, Sylvie Fraitag, Paul G. Kemps, Zofia Hélias-Rodzewicz, Somak Roy, Benjamin Bonsang, Allison L. Bartlett, Subhra Dhar, Martin Jankofsky, Jozef Zlocha, et al.

    Non-Langerhans cell histiocytoses are a diverse group of histiocytic diseases. Different entities are defined based on clinical, histopathologic, and/or molecular characteristics. This study aimed to define NTRK-rearranged histiocytosis. Through international collaboration, we investigated 50 cases of histiocytosis with pan-tropomyosin receptor kinase (pan-TRK) expression and/or in-frame NTRK rearrangement. We also analyzed 45 control xanthogranulomas using pan-TRK immunohistochemistry and targeted RNA sequencing. Slides were centrally reviewed; clinical and molecular data were collected. The 50 cases comprised 30 children and 20 adults with a median age of 11.5 years (range, 0-73 years) and a male predominance (64%). Most patients (88%) had disease limited to the skin, including a single skin nodule in 41 patients and multiple skin lesions in 3 others. Four newborns presented with skin lesions, hepatomegaly, and thrombocytopenia that required transfusions. The 2 remaining patients had life-threatening lesions of the brain or bronchus. All cases displayed xanthogranuloma histology, often including foamy histiocytes and Touton giant cells. Histiocytes stained positive for pan-TRK in 50 of 50 cases, whereas all 45 control xanthogranulomas without in-frame NTRK fusions stained negative. NTRK1 fusion partners included IRF2BP2 (23/46), TPM3 (12/46), SQSTM1 (3/46), PRDX1 (3/46), NPM1 (2/46), LMNA (2/46), and ARHGEF2 (1/46). Clinical outcomes were favorable, including spontaneous disease regression in 3 of 4 newborns with systemic disease, and rapid clinical response in both patients with a brain or bronchial tumor treated with the TRK inhibitor larotrectinib. This study advances the molecular characterization of histiocytoses and may guide the diagnosis and personalized treatment of patients.